-
RKTO share price: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
-
RKTO stock price change: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
-
RKTO market open/close: temporarily unavailable. We are sorry, but this information is temporarily unavailable.
Key terms
About RKTO
Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.
-
Market cap: $27.93M
A market capitalization up to $300 million places RKTO in the micro-capitalization category.
Key terms
Smart score
Latest RKTO news
No recent TipRanks articles are available for RKTO
No recent press releases are available for RKTO
RKTO Financials
-
RKTO total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Net income: -$12.47M (1Y), -$2.69M (Q1)
Net Income decreased 52.28% since last year and increased 0.16% since last quarter.
-
Earnings per share: -$0.90 (1Y), -$0.17 (Q1)
EPS increased 29.68% since last year and increased 1.62% since last quarter.
Key terms
RKTO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RKTO Competitors
-
How competitors are chosen
RKTO's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $27.93M
A market capitalization up to $300 million places RKTO in the micro-capitalization category.
